An EMA advisory panel has rejected expanding the use of Eli Lilly’s Emgality to include prevention of episodic cluster headaches. The Committee for Medicinal Products for Human Use (CHMP ...
UK cost-effectiveness agency NICE has said that Eli Lilly’s Emgality can be made available through the NHS for migraine prevention, the second drug in the CGRP inhibitor class to achieve that ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback